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Abstract 
Bone substitute materials permissive for trans-scaffold migration and in-scaffold survival of 
human bone-derived cells are mandatory to develop cell-engineered permanent implants to 
repair bone defects. In this study, we evaluated the influence on human bone-derived cells of 
the material composition and microstructure of foam scaffolds made from calcium aluminate 
using a direct foaming method allowing wide-range tailoring of the microstructure for pore 
size and pore openings. Human fetal osteoblasts attached to the scaffolds, migrated across the 
entire materials depending on the scaffold pore size, colonized and survived in the porous 
material for at least 6 weeks. The long-term biocompatibility of the scaffold material for 
human cells was evidenced by in scaffold determination of cell metabolic activity using a 
modified MTT assay, a repeated WST-1 assay and scanning electron microscopy. Finally, we 
demonstrated that the fetal cells can be covalently bound to the scaffolds using biocompatible 
click chemistry, thus enhancing the rapid adhesion of the cells to the scaffolds. Thus, the 
different microstructures of the foams influenced the migratory potential of the cells, but not 
cell viability, and the scaffolds were permissive for covalent biocompatible chemical binding 
of the cells to the materials, allowing either localized or widespread cellularization of the 
scaffolds for cell-engineered implants.  
 
Key words : permanent bone graft / biocompatibility / ceramic structure /  open pores / cell 
migration / human fetal osteoblasts / biocompatible click-chemistry 
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Introduction 
The demand of materials for the repair and substitution of damaged tissues, including bone 
tissue, is increasing. Presently the standard treatment for bone defects is autologous iliac crest 
bone grafting, but the need of a second surgery with its increased risk of infections, possible 
donor site morbidity, and also financial aspects, ask for the development of synthetic bone 
graft materials presently used in only about 15% of the cases.1 Therefore the development of 
scaffolds able to integrate in bone tissue and support bone regeneration across defects that are 
too large to heal naturally or when normal healing process is compromised 2 is mandatory for 
the success of reconstructive strategies for the treatment of critical-size bone defects.3,4  
To achieve these requirements two possibilities can be envisioned. The bone substitute is 
biodegradable and transitory and will be replaced by tissue from the organ, an approach which 
was mainly developed up to now. However, for large bone defects, such as seen in major bone 
loss, such a strategy is not always possible and permanent implants are requested which can 
be prepared into shapes reproducing the shape of the bone to be replaced and improve their 
integration in the tissue of implantation by promoting the interface continuity. These 
permanent implants must also be permissive for the growth of bone cells which should first 
functionalize the implant, providing cell-engineered implant materials, prior to implantation 
to improve its integration at the implantation site. The understanding of bone tissue structure 
allows for rational material design, able of mimicking the tissue structure and the specific 
biochemistry of bone. Bone is a highly organized tissue that assembles from nano- to 
macroscales to produce complex structural interconnected porous networks. Therefore, the 
development of permanent bone substitute materials presenting trans-scaffold channels 
permissive for migration and in-scaffold survival of human bone-derived cells are mandatory 
for ultimately develop a functional bone tissue for permanent implants to repair large bone 
defects. Such materials have also to ultimately support the formation of differentiated bone 
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cell structures inside the permanent implant. To obtain a physical support for permanent 
artificial bone tissue, synthetic, porous scaffolds must therefore be produced from inert 
biocompatible materials, such as alumina or titanium.5-7  
To develop permanent implants which have been engineered with human bone cells prior to 
implantation for the repair of human bone defects, histocompatibility problems of the cells of 
the implant with the recipient of the graft must also be considered. Human fetal cells have an 
interesting potential for therapeutic use for tissue engineering and regeneration, including 
bone tissue engineering, due to their rapid growth rate and their ability to differentiate in vitro 
into mature cells as well as their histocompatibility,8,9 eliminating the need for anti-graft 
rejection medication of the patients. However, presently, the developments for artificial bone 
implants performed with human fetal cells have used materials that were designed to be 
biodegradable. 10-12  
In the present study, our goals were to develop calcium aluminate scaffolds suitable for 
permanent bone replacement, displaying an open-porous channel microstructure allowing the 
engraftment and migration through the ceramics of human histocompatible bone-derived 
cells. The calcium aluminate scaffolds were produced from a modified direct foaming method 
13-19 which allows the production of macroporous scaffolds which are tailorable in pore size, 
microstructure and shape. In particular we aimed to determine the optimal pore sizes to allow 
survival and migration of these human bone-derived cells across the scaffolds. Therefore, we 
investigated the interaction of calcium aluminate scaffolds of varying composition and pore 
sizes first with human osteosarcoma cells in order to select the ceramic composition 
displaying optimal pore sizes and pore opening sizes, then with primary human fetal 
osteoblasts as models for histocompatible human bone-derived cells. We also determined 
whether the adhesion of the human fetal bone cells to these scaffolds can be improved by 
chemical functionalization using a biocompatible click-chemistry based covalent approach.  
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Experimental Procedures 
Preparation and characterization of the scaffolds 
Preparation of the scaffold materials 
The particles used to prepare the suspensions were a high-purity α-Al2O3 powder (HPA-
0.5w/MgO, Ceralox, Tucson, AZ) with an average particle size of 200 nm. The short chain 
amphiphile selected to in-situ modify the alumina particles was propyl gallate (Fluka AG, 
Buchs, Switzerland). Further chemicals used in the present study were hydrochloric acid, 
sodium hydroxide (both Titrisol, Merck, Germany) and deionized water (18.2 MΩ/cm). To 
consolidate the wet scaffolds, the calcium aluminate cement “CA-270” (Almatis GmbH, 
Ludwigshafen/Rhein, Germany) and the setting accelerator lithium carbonate (Fluka AG, 
Buchs, Switzerland) were used. 
Alumina suspensions were prepared by stepwise addition of alumina powder to an aqueous 
solution containing 27 mM NaOH and 22 mM propyl gallate. The suspension solids loading 
was initially fixed to 50 vol%. Homogenization and deagglomeration of the suspensions were 
carried out on a ball mill for 18 h using polyethylene milling bottles (1 L) and alumina balls 
(10 mm in diameter, weight ratio balls to suspension ≈ 2:1). After ball milling, three different 
suspensions were prepared as follows: the propyl gallate content was adjusted to 2, 1.2 or 1 
wt% to the amount of alumina particles by dissolving it in a NaOH aqueous solution 
displaying a pH higher than 10. These solutions were then added drop-wise to the ball-milled 
suspensions under stirring to avoid local particle agglomeration. Finally, the pH was set to 9.9 
and the solids loadings were adjusted to the respective volume fractions (12.7, 32.9 or 10.8 
vol%) by adding water to the suspensions. Immediately before the foaming step, the desired 
amount of cement powder (33.7, 4.3 or 26.3 vol%) and the setting accelerator lithium 
carbonate (5 wt% to the amount of cement) were added to the suspensions and dispersed 
under stirring.  
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Foaming of the cement containing suspensions was carried out using a household food 
processor (Kenwood, Major Classic) at maximum power level (800 W) during 3 min. The wet 
foams were then filled into cylindrical moulds, 10 cm in diameter and 5 cm high, and left to 
set at ambient temperature overnight in a moist atmosphere to prevent drying. After setting 
and drying, the specimens were sintered in an electrical furnace (HT 40/16, Nabertherm, 
Germany) at 1575°C for 2 h. The heating rate was controlled to 1°C / min and the cooling rate 
was controlled to 3°C / min. The sintered samples were then drilled into cylinders of 10 mm 
in diameter and 2 mm high, ultrasonicated in ethanol and acetone and dried at 110 °C. 
 
Characterization of the scaffold microstructure 
The porosity was determined by weighing a defined volume of a scaffold sample, and 
calculating the air content using the following formula: air content (vol%) = (1- 
ρmeasured/ρdense)∙100%, whereas ρ = density in g/cm3. To define the diameters of the pores and 
pore-openings, scanning electron microscopy (SEM) (LEO 1530, Zeiss Oberkochen in SE2 
mode and at low magnifications) micrographs were analyzed using the software Linear 
Intercept (TU Darmstadt, Germany), defining 250 intersections on 5 representative images. 
 
Chemistry 
Commercial reagents (Fluka, Aldrich, VWR, Switzerland) were used without further 
purification. Anhydrous solvents were obtained by filtration (PureSolv MD Series, Innovative 
Technology). TLCs for reaction monitoring were performed on Merck silica gel 60 F254 
plates, and spots were revealed with UV light and reaction with KMnO4 or ninhydrine. IR 
spectra were recorded on a Perkin-Elmer-1420 spectrometer. 1H NMR spectra were recorded 
on a Bruker-ARX-400 spectrometer (400 MHz) using MeOD as solvent and calibrated using 
the solvent's residual signal at 3.31 ppm as an internal reference. 13C NMR spectra were 
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recorded on a Bruker-ARX-400 spectrometer (100.6 MHz) using MeOD as solvent and 
calibrated using the solvent's residual signal at 49.0 ppm as an internal reference. Chemical 
shifts are expressed in parts per million (ppm) and coupling constants (J) in hertz. Mass 
spectra were obtained on a Nermag R-10-10C spectrometer with chemical ionization (NH3) 
and mode m/z (amu) [% relative base peak (100%)]. Semi-preparative HPLC was performed 
on a Waters Autopurification ZQ System equipped a 2767 Sample Manager, a 2525 Binary 
Gradient Module and a 2996 Photodiode Array Detector, coupled to Waters Micromass ZQ 
analyzer. The HPLC purifications were performed on XTerra Prep RP C18 (19 x 150) 
columns, using reverse-phase conditions (2 to 100% acetonitrile with 0.1% TFA over 20 
min). 
 
Chemical Syntheses 
5-[(6-aminohexyl)carbamoyl]benzene-1,2,3-triyl triacetate (3). Few drops of DMF were 
added to acetoxygallic acid (1 g, 3.4 mmol, 1 equiv) in dry DCM (6 mL). The solution was 
cooled to 0 °C and oxalyl chloride (0.31 mL, 3.7 mmol, 1.5 equiv) was added dropwise. After 
15 min the reaction mixture was allowed to reach room temperature and was stirred for 1 h.  
The reaction mixture was concentrated under reduced pressure and the residue was 
resuspended in dry DCM (4.5 mL). A solution containing N-Boc-1,6-hexadiamine (0.72 g, 
3.4 mmol, 1 equiv) and (i-Pr)2NEt (1.73 mL, 10.1 mmol, 3 equiv) in DCM (4.5 mL) was 
added dropwise at 0°C. After 15 min the reaction mixture was allowed to reach room 
temperature and was stirred for 1 h. The reaction mixture was concentrated under reduced 
pressure and purified by flash column chromatography (AcOEt/petroleum ether 1:1). The 
resulting product was dissolved in 4 M HCl in dioxane and stirred for 1 h at room 
temperature. HCl was coevaporated three times with diethyl ether to afford a white paste 
(mass: 400 mg, yield: 30 % for 2 steps). IR (film): 3265, 2935, 2860, 2225,1770, 1635, 1585, 
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1550, 1490, 1435, 1370, 1315, 1180, 1120, 1050, 1010, 975, 890, 870, 820, 760, 730, 700 590 
cm-1.1H NMR (400 MHz, MeOD): δ=7.64 (s, 1H, CH), 3.39 (t, 2H, CH2), 2.92 (t, 1H, CH2), 
2.30 (s, 9H, (CH3)3), 1.66 (m, 4H, (CH2)2), 1.44 (m, 4H, (CH2)2).13C NMR (101 MHz, 
MeOD): δ=169.50 (Cq), 168.35 (Cq), 133.72 (C(aromatic)), 121.00 (C(aromatic)), 40.81 
(CH2), 40.63 (CH2), 30.11 (CH2), 28.44 (CH2), 27.32 (CH2), 26.96 (CH2), 20.38 (CH3), 
19.96 (CH2). MS (ESI): HRMS (ESI): (m/z): calcd for C19H26N2O7+H: 395.1818, found: 
395.1823. 11,12-didehydro-5,6-dihydrodibenzo[a,e][8]annulen-5-yl(6-{[(3,4,5-trihydroxy 
phenyl)carbonyl]amino}hexyl) carbamate (5). 5-[(6-aminohexyl)carbamoyl]benzene-1,2,3-
triyl triacetate 3 (75 mg, 0.2 mmol, 1 equiv) was dissolved in DMF (18 mL) and carbonic 
acid, 5,6-dihydro-11,12-didehydro-dibenzo[a, e]cycloocten-5-yl ester, 4-nitrophenyl ester 4ref 
(80 mg, 0.2 mmol, 1 equiv) [ref] followed by triethylamine (0.08 mL, 0.6 mmol, 3 equiv) 
were added. The reaction mixture was stirred overnight at room temperature. DMF was 
removed under reduced pressure and the product was purified by flash column 
chromatography (AcOEt/petroleum ether 1:1 then 2:1) (mass: 150 mg, yield: 46 %). The 
resulting product (33 mg, 0.05 mmol, 1 equiv) was dissolved in THF at 0 °C and a 1 M 
solution of LiOH (0.15 mL, 0.15 mmol, 3 equiv) was added. The reaction was monitored by 
MS until total conversion of the starting material. The product was purified by HPLC 
((XTerra Prep RP C18, (25x150 mm Waters)) to give compound 5 (mass: 10 mg, yield: 38 
%). IR (film): 3275, 2935, 1695, 2595, 1515, 1450, 1330, 1200, 1135, 1035, 865, 755, 720, 
645, 585 cm-1.1H NMR (400 MHz, MeOD): δ=7.38 (d, 1H, aromatic, CH), 7.37-7.29 (m, 7H, 
aromatics, (CH)7), 6.82 (s, 2H, (CH)2), 5.42 (m, 1H, C(1’)H), 3.22 (dd, 1H, 2J= 15.0 3J= 2.0 
Hz (CH2)), 3.11 (t, 2H, 2J= 2.0 Hz (CH2)), 2.82 (dd, 1H, 2J= 15.0 3J= 3.8 Hz (CH2)), 1.60-
1.29 (m, 10H, (CH2)5).13C NMR (100 MHz, MeOD): δ=169.12 (Cq), 156.64 (Cq), 152.34 
(Cq), 151.03 (Cq), 136.52 (Cq), 129.57 (C(aromatic)), 127.92 (C(aromatic)), 127.81 
(C(aromatic)), 126.89 (C(aromatic)), 126.84 (C(aromatic)), 125.74 (C(aromatic)), 125.48 
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(C(aromatic)), 124.99 (C(aromatic)), 123.47 (C(aromatic)), 112.39 (Cq), 109.57 (Cq), 76.40 
(CH), 45.74 (CH2), 40.28 (CH2), 39.36 (CH2), 29.40 (CH2), 29.10 (CH2), 26.25 (CH2), 26.06 
(CH2).MS (ESI): HRMS (ESI): (m/z): calcd for C30H30N2O6+H: 515.2182, found: 515.2180. 
[α]D25 = 0.1 (c=0.004, CH2Cl2). 
 
Chemical coating of the scaffold discs 
Disks (d= 2.5 cm, h= 0.5 cm) of aluminium oxide scaffolds were incubated in an aqueous 
solution of compound 5 at increasing concentrations (0, 5 and 10 µM) for 24 h at room 
temperature in the dark under slight stirring. The disks were washed three times with water 
and dried under vacuum for 24 h.  
 
Cell assays 
Cell cultures and treatments  
Human SaOs and U2Os osteosarcoma cells were obtained from the American Tissue Culture 
Collection (ATCC, Manassas, VA, USA). Human fetal osteoblasts were derived by the 
explant technique from the femoral bone of a 12-week old fetus according to a protocol 
accepted by the Lausanne Hospital and University Ethics Committee and with the mother’s 
oral and written approval (protocol No 51/01, 2008). These cells were used at passage 6. Cells 
were routinely grown in DMEM medium containing 4.5 g/L glucose, 10% fetal calf serum 
(FCS) and antibiotics (all from Gibco, Basel, Switzerland). On the day of the experiments, 
cells were detached for the flasks using trypsin-EDTA (Gibco), washed once in complete 
culture medium and suspended in complete culture medium. Then, 50-75 μL (~500x103 
cells/scaffold) of the cell suspension were slowly added on the top centre of the scaffold discs 
(1 cm diameter) inserted into a well of a 24-well culture plate (Costar, Corning Inc, NY, 
USA) until the red cell suspension was completely absorbed by the scaffolds. Then, 2x100 μL 
of complete culture medium was added. After 6 hours, 200 μl of complete culture medium 
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were added on the bottom of the culture well. Estimation of cell behavior in the scaffolds was 
determined at different times post seeding (see below).  
 
Evaluation of cell repartition in the scaffold compartments  
The quantification of cell repartition in the 3 compartments of the culture system, i.e. the 
scaffold, the bottom of the cell culture well under the scaffold and the cells and/or fragments 
from dead cells in the culture medium, was performed by adapting a previously published 
radioactive-labeling procedure for cell-cell adhesion20 to the scaffold system. Briefly, cell 
DNA was stably pre-labeled for 24-144 h (depending on the rate of cell proliferation) by 
tritiated thymidine (0.5 μCi/mL [3H]-thymidine, Amersham Pharmacia, Dübendorf, 
Switzerland), then added to the scaffolds as described above. At the end of the incubation of 
cells in the scaffolds, 25 μL of the culture medium of the cell-scaffolds was removed and 
dissolved in 0.5 mL 1% SDS-0.1 M NaOH. To quantify cell-associated radioactivity 
repartition in the foam system, cell-scaffolds were removed from their wells, washed twice in 
0.9% NaCl, and then immersed for 2 h in 0.5 mL SDS-NaOH. The cell layers at the bottom of 
the wells were treated in the same manner. Five mL of scintillation cocktail (Optiphase Hisafe 
3, Perkin-Elmer, Shelton, CT, USA) were added to all samples and radioactivity was 
quantified in a beta-counter (WinSpectra, Wallac, Germany). Means + standard deviation (sd) 
were calculated. 
 
Evaluation of cell survival and metabolic activity in scaffolds using the MTT assay 
To quantify metabolically active cells in the scaffolds, MTT reduction assay for in scaffold 
end-point determinations was used. Briefly, scaffolds loaded with cells were exposed to 0.25 
mg/mL (final concentration) MTT ((3,4,5-dimethylthiazol-yl)-2,5-diphenyl tetrazolium, 
Sigma, Buchs, Switzerland) added to complete culture medium for 1 h (osteosarcoma cells) or 
    11 
4 h  (human fetal osteoblasts) and the blue-violet precipitated formazan in the scaffolds was 
fixed in 4% buffered paraformaldehyde and photographed. Alternatively, MTT reduction was 
quantified according to a modification of a previously described procedure.21 Following 
exposure to MTT for 2 h, the scaffolds were washed twice in PBS and immersed in 0.1 N HCl 
in isopropanol to dissolve the blue precipitated formazan and the extracts were quantified in a 
multiwell-plate reader (iEMS, Labsystems) at 540 nm.  
 
Evaluation of cell proliferation in the scaffolds using Alamar Blue 
To quantify osteosarcoma cell proliferation in the scaffolds, the Alamar Blue reduction test 
was used. This assay allows repeated determination of cell metabolic activity in the same 
sample, providing a cell proliferation time-course. One day after seeding, at day 1 after 
seeding the scaffolds containing the cells were transferred to a new well containing 0.5 mL of 
fresh complete culture medium, then 40 µL Alamar Blue (Serotec, Düsseldorf, Germany) 
were added and the fluorescence was measured in 100 µL aliquots removed at 0 min and 45 
min after the addition of the Alamar Blue in a multiwell-plate fluorescence reader (Cytofluor, 
PerSeptive BioSystems) at λex/λem = 530 nm/580 nm, respectively. Then the cell-scaffolds 
were transferred in fresh complete culture medium to continue the incubation for another day, 
and the process was repeated at day 2 and at day 3. Experiments were repeated at least twice. 
 
Evaluation of long-term survival and proliferation of fetal osteoblasts in the scaffolds using 
the WST-1 assay 
For long-term cultures (6 weeks) of fetal osteoblasts a repeated WST-1 (2-(4-iodophenyl)-3-
(4-nitrophenyl)-5-(2,4-disulphophenyl)-2H-tetrazolium, Roche Diagnostics, Rotkreuz, 
Switzerland) assay was performed at 2 week intervals. In a 24-well plate, fetal osteoblasts 
were seeded on S3 scaffolds (~500x103 cells/scaffold) and leave to adhere and grow in 
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complete culture medium as above. The culture medium of all cell-scaffolds was changed 
once a week to fresh complete medium. At 2 week intervals, the culture medium of 2-3 
scaffolds was removed, 500 µL of fresh complete medium containing 50 µL WST-1 added 
and the scaffolds returned to the cell culture incubator. After 5, 30, 60 and 120 min, 100 µL of 
WST-1-culture medium were removed and added to a well of a sterile 96-well plate. Optical 
density of the supernatants was measured at 450 nm in a multiwell-plate reader (iEMS Reader 
MF) and the medium was returned to their respective wells and culture continued until the 
next time-point. At the end of the measurements the metabolic activity of cells in the scaffolds 
was controlled using a in-scaffold MTT test.  
 
Scanning electron microscopy (SEM) of cells inside the scaffolds 
Cells were seeded onto the scaffolds as described above and incubated for 24 h to 6 weeks in 
complete culture medium. Scaffolds containing the cells were then washed twice in PBS and 
fixed in 2 mL of 4% buffered paraformaldehyde. The scaffold disks were broken in half and 
their cross section analyzed by means of SEM (LEO 1530, Zeiss Oberkochen). To visualize 
the cells, mixed mode detection (combining the SE2 and Inlens signal) was used at an 
acceleration voltage of 3 kV. 
 
Osteogenic cell differentiation 
Human U2Os cells, SaOs cells or fetal osteoblasts were grown in differentiating medium 
(adapted from ref. 22), consisting in complete culture medium supplemented with 
dexamethasone (10 nM final concentration, Sigma-Aldrich), 2-phosphate-ascorbic acid (0.15 
mM final concentration, Sigma-Aldrich) and β-glycerophosphate (0.25 mM or 2.5 mM, final 
concentration, Sigma-Aldrich) for 7 or 14 days. Medium was changed once a week to 
complete differentiating medium, then the cell layer was washed and either extracted in RIPA 
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buffer for western blotting experiments or in 15 mM Tris pH 8.8 - 0.1% Triton X-100 (Fluka, 
Sigma-Aldrich) for 10 min at 4°C for alkaline phosphatase activity determination. Protein 
content of the extracts was quantified using the BCA kit (BCA Protein Assay Kit, Pierce, 
Rockford, USA) and bovine serum albumin as standard.  
To determine alkaline phosphatase activity (adapted from ref. 23), 10-200 µL of cells extracts 
adjusted to 200 µL with 15 mM Tris pH 8.8 were added in wells of a 96-well plate, then 10 
µL of para-nitrophenyl phosphate (pNp, stock solution 1 mg/mL H2O, Sigma-Aldrich) were 
added, and the increase in absorbance at 405 nm was recorded for 30 min at 37 °C in a 
multiwell plate reader (iEMS, Labsystems). Enzymatic activity was expressed as units of 
enzymatic activities [1U= 1 µmole pNp produced/min, using an ε=1.8 104 M-1 cm-1 for p-
nitrophenol]. U/mg proteins were calculated and the enzymatic activities of differentiated 
cells were compared to the enzymatic activities of undifferentiated cells. 
For determination of collagen type I by western blotting, cells were grown in 9 cm diameter 
Petri dishes, then the cell layers were washed with cold PBS and lysed in 200 µL of lysis 
buffer (150 mM NaCl, 2 mM EDTA, 0.5% Triton X-100, 50 mM Tris-HCl, 2 mM vanadate, 
50 mM NaF, pH 7.2) and 10 µL of proteinase inhibitor cocktail (Sigma-Aldrich), scraped 
with a cell scrapper, extracted by 4 cycles of freeze/thawing and centrifuged at 10 000 rpm 
(10 000g) at 4 °C for 10 min. Protein content in the supernatants was quantified using the 
BCA reagent and an extract volume corresponding to 30 µg proteins was heated for 5 min at 
95 °C in the absence of a reducing agent, submitted to SDS-PAGE and transferred onto a 
nitrocellulose membrane (Whatman, Dassel, Germany). The membranes were blocked with 
5% fat-free milk in PBS, washed in 0.05% Tween-20 (Sigma-Aldrich) in PBS and incubated 
overnight at 4 °C with a polyclonal anti-human collagen type I proα2 chain antibody (Abcam, 
Cambridge, UK; anti-Col1A2, ab96723; diluted 1:2500 in 1% fat-free milk and 0.05% 
Tween-20 in PBS) then exposed for 60 min to peroxidase-conjugated anti-rabbit antibody 
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(Promega, diluted 1:5000) and visualized using chemiluminescence (ECL, GE Healthcare, 
Amersham, UK). To control for loading, the membranes were stripped by successive 
incubation in 0.1 M glycine pH 2.3, 1 M NaCl in PBS and 0.05% Tween-20 in PBS, blocked 
for 1 h with 5% fat-free milk in PBS and exposed to a monoclonal anti-human α-tubulin 
antibody (Abcam, diluted 1:10000) for 1 h, then to a peroxidase-conjugated anti-mouse 
antibody (Sigma-Aldrich, diluted 1:5000) at rt and treated as above. For the purpose of 
comparison human skin fibroblasts 24 were treated under the same conditions. 
 
Click-reaction on the biomaterial 
L-azidohomoalanine (AHA) was purchased from Invitrogen, bovine serum albumin (BSA), 
from Sigma-Aldrich, Buchs, Switzerland. Nine-cm Petri dishes (Costar) were coated with 
1000 µg/mL Rat Tail collagen I (Invitrogen) according to the supplier's protocol and human 
fetal osteoblasts were then grown in the dishes for 24 h until the cells are 80-90 % confluent. 
The cells were washed with PBS and incubated in methionine-free DMEM culture medium 
(Gibco) for 60 min to deplete methionine reserves. Then the cells were incubated overnight in 
the presence of AHA (50 µM final concentration) in fresh complete methionine-free culture 
medium. The culture medium was removed and the cell layers were washed twice with PBS. 
Collagen coating was degraded by adding 0.1 mg/mL collagenase (Sigma-Aldrich) in PBS at 
37 °C for 45 min. The osteoblasts were then counted. Three mL of the cell suspension (105 
cells/mL) were added on unfunctionalized or functionalized scaffolds with compound 5, in a 
6-well plate (Costar) and incubated for 1 h at rt under slight agitation. The disks were washed 
once with PBS, fixed in cold methanol (-20°C) for 5 min and incubated in 5 % BSA for 1 h at 
rt. Cells were stained for 5 min at rt with a solution containing 0.05 % crystal violet (Sigma-
Aldrich) and 1.5 % glacial acetic acid in water.  Cells were imaged by stereomicroscopy 
(MZ16 FA Leica/DFC 480 Leica, 0.63 X and 1.6 X, zoom 72 X), 3 pictures for each 
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treatment were taken and the cell number was evaluated using the Image J software.  
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Results  
Preparation and characterization of the scaffolds 
We have previously designed techniques to prepare porous ceramics via a direct foaming 
method.13-17 The adaption of this foaming method allowed the production of macroporous 
scaffolds which are tailorable not only in pore size, but also in pore interconnectivity.18,19  In 
the present study, we made use of this direct foaming method to produce scaffolds from 
calcium aluminate and evaluated them as potential permanent bone graft materials. To obtain 
porous scaffolds with different microstructures, ceramic foams with varying pore sizes and 
porosities were produced from slightly varying compositions (Table 1). The sintered 
specimens could easily be machined into different shapes (Figure 1a) and the SEM 
micrographs showed an open porosity, resulting in a network of interconnected pores (Figure 
1b-d). Size distributions of the scaffolds pores and pore-openings were determined (Figure 
2). As shown in Table 1 and Figure 2, scaffolds S1 and S2 are equal in average pore diameter 
(170 µm) and display pore openings (or windows) of similar sizes (50 µm and 60 µm in 
diameter, respectively). The microstructure of scaffold S3 has a two to three times larger 
average pore size of 460 µm and pore openings of 95 µm. The porosity (or air content) of the 
different scaffolds is the same for scaffolds S1 and S2 (76 vol%) and is higher for scaffold S3 
(86 vol%). Thus by varying the suspension composition, foam scaffolds with different 
microstructures and porosities were obtained.  
 
Interaction of human osteosarcoma cells with the scaffolds 
U2Os and SaOs human osteosarcoma cells are widely used as cell models for human bone-
derived cells and are more easily available than primary human bone cells. Thus, in order to 
select the scaffolds with optimal characteristics allowing human bone cells to adhere, survive 
and migrate, these cells were used as initial screening tools. To evaluate the biocompatibility 
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of the scaffold materials, the metabolic activity of human U2OS osteosarcoma cells 1 to 3 days 
after seeding in the 3 scaffolds was determined using the Alamar Blue assay, which allows 
repeated evaluation of the same samples (Figure 3). Cells were seeded in the scaffolds by 
placing complete cell culture medium containing phenol red and cells onto the top of the 
scaffolds. After the absorption of the cell culture medium in the scaffolds, the red cell culture 
medium slightly drained from below the three scaffolds, indicating that the microstructures of 
the scaffolds were permissive for the flowthrough of cell culture medium. Under an inverted 
optical microscope after 1 day culture, few cells were seen adhered on the bottom of the 
culture wells under scaffolds S1 and S2, while more cells were found on the bottom of the 
wells under scaffold S3. Thus, the initial trans-scaffold migration of the cells, as expected, 
was mainly determined by the pore size and the size of the inter-pore openings of the 
scaffolds. The cells which migrated outside the 3 scaffolds were well spread and attached to 
the well plate bottoms, were metabolically active as demonstrated using a MTT test (not 
shown), suggesting that the cell viability was not affected by the scaffold material during 
initial cell migration across the scaffolds.  
In order to determine the repartition of cells and cell components in the 3 compartments of the 
scaffold culture system, i.e. the cells in the scaffolds, the cells on the bottom of the cell culture 
wells under the scaffold, and the culture medium bathing the scaffolds, the DNA of U2Os and 
SaOs human osteosarcoma cells was stably pre-labeled with radioactive [3H]-thymidine and 
the radioactivity was quantified in the different partitions of the cell-scaffold systems 
(Supplementary Information, Table S1). For all cell-scaffolds, the amount of radioactivity 
measured in the scaffolds was always much higher than in the well plate bottoms or in the 
culture media, for all time periods and both cell lines, strongly suggesting that most cells were 
retained inside the scaffolds. Thus, ceramic calcium aluminate scaffolds are good substrates 
for long-term adhesion and survival of human bone-derived cells.  
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The aspect of human SaOs and U2Os osteosarcoma cells grown for either 1 day or 4 days in 
the three different scaffolds was examined using SEM (Figure 4A). The micrographs showed 
that the cells adhered to and spread onto the ceramic surface of all 3 scaffolds, indicating a 
good acceptance of the scaffold material by the living cells. To determine if the cells were 
able to migrate across the whole scaffold, U2Os cells were seeded on the top of scaffold S3 
(Figure 4B, arrow) and grown for 4 days in the scaffolds, then after fixation in buffered 
paraformaldehyde, the scaffold was broken in the middle and the whole fracture section 
examined by SEM (Figure 4B, left panel), showing cells located at different levels of the 
scaffold from the initial seeding point at the top of the scaffold. The cells were examined at 
higher magnification (Figure 4B, panels 1 to 5) showing well spread cells on their substrate 
at all levels of localization in the scaffolds. Thus, the SEM images and the proliferation 
experiments strongly suggested biocompatibility of the different scaffold materials and 
permissiveness for living cell migration across the scaffolds. In particular scaffold S3 
presented with optimal properties for cell migration, and was selected for further evaluation 
using human primary fetal osteoblasts. 
 
Interaction of human fetal osteoblasts with the scaffold S3 
Human primary fetal osteoblasts derived from the femoral bone of a 12-week old fetus 25,26 
were first compared to human osteosarcoma cells for their expression of differentiation 
markers of bone cells, either under standard culture conditions or in differentiating cell culture 
medium. Three markers of the human osteoblast cell lineage were analyzed: the expression of 
the proα2 chain of type I collagen (Figure 5A), alkaline phosphatase activity (Figure 5B) and 
the cell ability to deposit calcium (Figure 5C). Collagen type I is found in most connective 
tissues and defects of this protein have been involved in disorders of the bone, such as 
osteogenesis imperfecta. Human skin fibroblasts were used as positive controls of the 
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expression of collagen type I. Human fetal osteoblasts and skin fibroblasts expressed collagen 
type I, but not the two human osteosarcoma cells lines. This expression could not be induced 
when the osteosarcoma cells were grown in differentiating medium for 7 to 14 days, and no 
further increase in collagen I expression by fetal osteoblasts grown in differentiating medium 
for up to 14 days was observed (results not shown). Alkaline phosphatase activity was 
increased over basal activity level by a factor 2 in the two human osteosarcoma cells and by a 
factor 20 in the fetal osteoblasts by culturing them for up to 14 days in differentiating 
medium. It must be underlined that the basal alkaline phosphatase activity of SaOs cells is 
much higher than that of the two other cell lines. Human fetal osteoblasts were able to deposit 
calcium. Therefore these human bone-derived histocompatible fetal cells represent human 
bone-derived cells able to differentiate into bone cells, and are relevant models to evaluate the 
interaction of human primary bone-derived cells with the newly prepared S3 scaffolds. 
The radioactivity of human fetal osteoblasts stably pre-labeled with radioactive [3H]-
thymidine was quantified in the cells in the S3 scaffold, in the cells on the bottom of the cell 
culture wells under the scaffold, and in the culture medium bathing the scaffolds 2 days and 6 
days after seeding (Figure 6A). As for human osteosarcoma cells, the amount of radioactivity 
measured in the scaffolds was much higher than in the two other compartments of the system, 
but some cells could be detected on the bottom of the culture wells, under the scaffold. Six 
days after seeding in scaffold S3, the fetal osteoblasts were examined using SEM (Figure 
6B). The micrographs showed that the cells adhered to and spread onto the ceramic surface of 
the scaffolds, able to make cell bridges across the pores in the image which we selected as an 
example. Then, the long-term proliferation of human fetal osteoblasts in the scaffolds was 
evaluated using a WST-1 assay demonstrating that the cells proliferated in the scaffolds for up 
to 6 weeks (Figure 6C). The proliferative properties of human fetal osteoblasts were 
maintained for cells seeded in the scaffold S3 in differentiating medium and were comparable 
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to the proliferation of cells grown in the same medium on cell culture plastic (results not 
shown). To confirm the long-term in-scaffold viability and metabolic activity of fetal 
osteoblasts after culture inside the scaffolds, the human fetal osteoblasts were grown for 6 
weeks in scaffolds S3, or scaffold S1 for the purpose of comparison (Figure 6D). Then a 
modified in-scaffold MTT assay (which is based upon the reduction of the soluble yellow 
MTT molecules to a violet formazan precipitate by the respiratory chain of living cell 
mitochondria), was developed. The cell-associated violet precipitate proved cell metabolic 
activity and viability inside the scaffold S3 for long period of time (Figure 6D). The violet 
cell staining on both the top and bottom sides of scaffold S3 suggested that viable cells still 
colonized the whole scaffold after 6 weeks, whereas for scaffolds S1, only the up side, where 
the cells were initially seeded, but not the down side of the scaffolds was stained. Thus a 
large-porous microstructure facilitates primary human fetal osteoblasts migration across the 
scaffolds and allows their survival in the scaffolds for at least 6 weeks.  
In order to further determine the repartition of primary human fetal osteoblasts in the 
scaffolds S3 6 weeks after seeding, the scaffolds were fixed in buffered paraformaldehyde, 
broken in the middle and the whole fracture section examined by SEM. Low magnification 
(Figure 7a) was used to visualize showing cells located at different levels of the scaffold 
(highlighted by white circles and numbers) from the initial seeding at the top of the scaffold. 
Then, the cells were examined at higher magnification (Figure 7b, panels 1 to 9), showing 
well spread and viable cells at all levels of localization in the scaffolds.  
Therefore the porous calcium aluminate ceramic scaffolds that we developed, in particular 
scaffold S3, and evaluated displayed the requested characteristics that we initially defined: 
permissiveness for human bone cells trans-scaffold migration and in-scaffold survival and 
proliferation. However, we observed that the addition of human bone-derived cells, either 
osteosarcoma cells or fetal osteoblasts, on the top side of the scaffolds S3 resulted in the rapid 
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appearance of a few cells on the bottom side of the scaffolds, suggesting that their adhesion 
was not rapid enough to ensure the optimal cellularization of these scaffolds with bone cells 
and should be improved 
 
Click-functionalization of the scaffolds and adhesion of human fetal osteoblasts    
We have previously shown that alumina-based scaffolds can be chemically functionalized 
with gallate-based ligands.27 We have also previously shown that human fetal osteoblasts can 
be chemically functionalized using biocompatible click chemistry.28 Thus, in order to enhance 
the adhesion of the fetal osteoblasts to the scaffold, we combined these two approaches by 
designing and synthesizing (Scheme 1) compound 5, an hetero-bifunctional ligand bearing a 
gallate functionality and an activated alkyne. The alumina scaffolds were functionalized with 
compound 5, then the azido-modified human fetal osteoblasts (106 cells per scaffold) were 
added to scaffolds which were either unfunctionalized or had been pre-functionalized with 
compound 5 (5 or 10 μM). After the washing and fixation steps, the cells were stained with 
crystal violet (Figure 8A). Cell adhesion to the scaffolds was imaged with a stereomicroscope 
and the number of adhered cells was quantified by the Image J software (Figure 8B). 
Quantification of the number of adhered cells showed that the functionalization of the 
scaffolds with compound 5 increased the number of adhered cells, with a very strong 
dependency on the amount of compound 5 (r = 1.00, 10 μM vs 5 μM) used for the 
functionalization of the scaffolds. The observed increase of the number of adhered cells was 
statistically significant (p< 0.001). 
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Discussion 
Major challenges in the development of permanent bone substitutes are biocompatibility and 
permissiveness of the implant for the migration across its whole structure of bone and bone-
associated cells to ultimately allow the development of adequate bone-mimicking tissue and 
improve integration of the implant in the tissue. Many previous studies have addressed the 
development of biodegradable materials for small bone defects, whereas studies of 3-
dimensional scaffolds able to support the survival of bone-derived cells for permanent 
replacement of bone defects are scarcer. These permanent scaffolds should be able to 
reproduce the structure of the bone matrix, and to be modeled in shapes and characteristics 
similar to the bone tissue to be replaced, while maintaining their structural stability. The 
ability of such scaffolds to form a porous interconnected network spanning the entire structure 
is also requested in order for relevant cells to develop into a functional bone tissue. Ceramics-
based materials fulfill many such requirements and are osteoconductive and biocompatible. 
However, few ceramics with controlled pores spanning the scaffold structures and allowing 
the migration and adhesion of cells across the whole structure, have presently been described. 
Most described methods to produce porous scaffolds use organic materials and their 
subsequent elimination from the structure during the sintering process. Previous work by 
others has shown that titanium-based metal implants of the second generation can be made 
more porous to allow bone growth through the implant.29,30 Titanium-based foams are made 
by impregnating polyurethane forms with titanium powder, hardening of the structure and 
washing away of the polyurethane, resulting in a material with lower stiffness than solid 
titanium and which is less brittle than ceramic materials. The materials performed well as 
permanent implants for disc replacement in animal models.31-33 Ceramics derived from 
calcium phosphate mimics the mineral structure of bone, and bone cells were shown to 
recognize and bind to such ceramics.34,35 Calcium phosphate-based ceramics have been 
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previously shown to display bone integration properties 36,37 and calcium aluminate further 
increases osteointegration.38,39 Alumina ceramics, including porous alumina allows the 
attachment, growth and differentiation of bone cells, the materials grain microstructure being 
important for cell behavior, including for a human bone-derived cell line.5-7 The surface 
reactivity of bioactive glass ceramics and the sintering process were shown to affect 
interaction with human osteoblasts, and ultimately their bone integration potential.40  
In order to develop a permanent bone replacement, which displays an open-porous 
microstructure allowing the establishment of a continuous cellular network of bone-derived 
cells, we developed a different methodology based on calcium aluminate scaffolds produced 
from a recently modified direct foaming method.13-19,41 In order to meet the needs and 
challenges of open-pores microstructures required, the so-called limited coalescence 
phenomenon was exploited, where bubbles start to disproportion and coalesce instantly after 
foaming, until a new equilibrium is reached.12-17 Then, upon bubble growth, the foam lamellae 
start to thin, layer by layer, until the bubble eventually ruptures. This second phenomenon, 
which is called partial coalescence, can occur during the limited coalescence step, especially 
if the inter-particle forces are attractive. The freezing of this transitory state of partial 
coalescence will then lead to an open-porous microstructure. For the present study, foams 
made from alumina particles were combined with a calcium aluminate cement reaction.18,19 
Upon setting and sintering, open-porous scaffolds with different microstructures, which can 
be machined into the desired shapes, were produced, characterized and engineered with 
human bone-derived cells. In the present feasibility study, we investigated three scaffolds 
with various pores and pore openings for biocompatibility and the adhesion behavior, the in-
scaffold viability and the metabolic activity of human bone-derived cells, using first human 
osteosarcoma cells to select the scaffolds with optimal porosities, then primary human fetal 
osteoblasts 25,26 as potential histocompatible cells 9 for cell-engineering the scaffolds prior to 
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their implantation into patient receivers. These studies demonstrated the biocompatibility of 
the three scaffolds for human bone-derived cells whatever their fine chemical and physical 
characteristics, and importantly also demonstrated that the scaffold porosities determined the 
potential of cells to migrate across the entire scaffolds and form functional cellular networks 
across the entire structure. Therefore these experiments allowed defining a minimal pore 
opening limit around 100 μm in order to allow cell passage and whole structure colonization. 
Following this passage, cells were still alive after long-term culture, and cells inside the 
scaffolds demonstrated a steady potential for proliferation without any sign of cytotoxicity. 
The SEM observations showing cells throughout the entire scaffold proved that open channels 
span throughout the whole scaffold structures and that the material is permissive for human 
cell migration and proliferation. SEM also confirmed that the cells adhered to and were well 
spread onto the ceramic surface, again indicating a good acceptance and biocompatibility of 
the scaffold materials by living human primary fetal cells and provided a proof of concept for 
their potential as permanent implants for bone tissue engineering.  
However, the adhesion of human bone-derived cells onto the large pore scaffolds was not 
rapid enough to ensure the optimal cellularization of these scaffolds. Combining our previous 
observations that alumina-based scaffolds can be chemically functionalized with gallate-based 
ligands,27 and that human fetal osteoblasts can be chemically functionalized using 
biocompatible click chemistry,28 we showed here that the number of human fetal osteoblasts 
adhering to the scaffolds can be enhanced by their covalent binding to the scaffolds using an 
hetero-bifunctional ligand and biocompatible click-chemistry. Therefore, we show here that 
large-pore alumina-based scaffolds and primary human fetal cells derived from the fetal bones 
are an interesting potential source of bone precursor cells to prepare permanent cellularized 
bone implants for tissue engineering, using chemical functionalization of the scaffolds. This 
acceptance of the developed scaffolds by such cells is encouraging for further development 
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toward bone tissue engineering.  
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Tables 
 
  scaffold    average pore average pore porosity   Al2O3    CA-270 ratio cement 
     No        size [µm] opening [µm]  [vol%]    [wt%]    [wt%]   to alumina 
________________________________________________________________________   
     S1        170        50       76       12.7        33.7        2.7 
     S2        170        60       76       32.9          4.3        0.1 
     S3         460        95       86       10.8         26.3        2.4 
________________________________________________________________________ 
 
Table 1: Physicochemical characteristics of the different scaffolds. 
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Schemes: 
 
 
 
Scheme 1: Synthesis of compound 5 for the click-reaction of human fetal osteoblasts on 
scaffolds. 
Acetoxygallic acid 1 was first converted into the corresponding acyl chloride by reaction with 
oxalylchloride in presence of DMF and then coupled to N-Boc-1,6-hexadiamine to afford 
intermediate 2.  After deprotection of the amine under acidic conditions, the compound 3 
reacted with 6-dihydro-11,12-didehydro-dibenzo[a, e]cycloocten-5-yl ester, 4-nitrophenyl 
ester 4 in the presence of triethylamine. Finally, deprotection of the three-hydroxyl groups 
under basic conditions provided the desired compound 5 which was further used for the 
functionalization of the biomaterial and the click reaction with human fetal osteoblasts. 
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Figure Legends 
Figure 1: Macroscopic and microscopic aspect of the scaffolds. 
Upper panel: a) macrophotographs of the three different scaffold materials (from left to right: 
scaffold S1, scaffold S2 and two pictures of scaffold S3);  
Lower panels: SEM micrographs of b) scaffold S1; c) scaffold S2; d) scaffold S3. 
 
Figure 2: Size distribution of the pores and pore openings for the 3 different scaffolds.  
To define the diameters of the pores and pore-openings, SEM micrographs at low 
magnifications were analyzed (grey bars) using the software Linear Intercept, then the 
cumulative values were calculated (solid lines).  
 
Figure 3: Determination of the proliferation of human U2Os osteosarcoma cells 1 to 3 days 
after seeding in the scaffolds.   
To evaluate for cell proliferation in the scaffolds, U2Os cells were seeded onto one of each of 
the three scaffolds (S1, S2, S3) and culture was performed for 24 h. AlamarBlue was added to 
the cells-scaffolds and fluorescence measured after 45 min. Then, fresh medium was added 
and culture continued and the process was repeated after 48 h and 72 h of cell culture in the 
scaffolds, allowing the same cell-scaffold system to be sequentially analyzed on day 1, day 2 
and day 3. ♦ scaffold S1; □ scaffold S2; ▲ scaffold S3. 
 
Figure 4: SEM micrographs of human osteosarcoma cells inside the scaffolds. 
A. Human SaOs (upper panels) and U2Os (lower panels) osteosarcoma cells were grown in 
scaffold S1 (S1), scaffold S2 (S2) or scaffold S3 (S3) for, respectively, 1 day or 4 days. After 
fixation in paraformaldehyde, the scaffolds were split and SEM pictures of the cells inside the 
scaffolds taken, showing that the cells adhered and spread onto the ceramic materials. White 
    34 
arrows indicate the cells. 
B. Human U2Os osteosarcoma cells were unidirectionally (red arrow) seeded on the top of 
scaffold and grown for 4 days in scaffold S3. Then the scaffold was fixed in 
paraformaldehyde, split in the middle and the fracture section was scanned by SEM. Isolated 
cells (labeled 1-5) are shown at higher magnification in panels 1-5. For improved viewing, the 
cell shapes are surrounded by a white line.  
 
Figure 5: Expression of collagen I, alkaline phosphatase activity and calcium deposits by the 
the human bone-derived cells. 
A. Human cells (skin fibroblasts, fetal osteoblasts (FSOS), and osteosarcoma cells (SaOs, 
U2Os) were grown to confluence in Petri dishes and extracted. Cell extracts were submitted to 
western blotting experiments using an anti-human collagen I antibody, and loading was 
controlled using an anti-human α-tubulin antibody. When the cells were grown in 
differentiating medium for 7 to 14 days, no induction of collagen I expression by U2Os and 
SaOs cells and no further enhancement of collagen I expression by FsOs cells by 
differentiation medium was observed (not shown). 
B. Alkaline phosphatase activity (U/mg protein) was determined in human fetal osteoblasts 
(FsOs), and osteosarcoma cells (SaOs, U2Os) grown either in standard or in differentiating 
culture medium (diff) for 10 days. Means of triplicate wells + sd were calculated. 
Experiments were repeated 3 times with similar information. No further enhancement of 
alkaline phosphatase activity by FsOs cells by differentiation medium was observed for 
longer culture in differentiation medium (not shown). 
C. Kossa staining of calcium deposits (black staining, arrows) in terminally differentiated, 
non-proliferating human fetal osteoblasts. Cell cytoplasms are stained light pink and cell 
nuclei dark pink. 
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Figure 6: Human fetal osteoblasts grown in scaffold S3 are retained, proliferate and are 
metabolically active in the scaffolds for at least 6 weeks.  
A. Human fetal osteoblasts were prelabeled with [3H]-thymidine, then grown in the scaffolds 
for 2 or 6 days. Radioactivity was quantified in extracts of the cells in the scaffolds (dark 
grey), associated to the cells at the bottom of the wells (light grey) and in the soluble culture 
media (black). The experiments were repeated twice, with comparable information.  
B. Human fetal osteoblasts were grown in scaffolds S3 for 6 days. After fixation in 
paraformaldehyde, the scaffolds were split and SEM pictures of the cells inside the scaffolds 
taken, showing that the cells adhered and moved into the ceramic materials, spanning across 
the pores in the selected SEM picture.  
C. Human fetal osteoblasts were seeded on scaffold S3 and grown in culture medium. After 7, 
14, 21 and 38 days of osteoblast culture in the scaffolds, WST-1 was added to the culture 
medium bathing the scaffolds (2-3 scaffolds per time-point) and absorbance kinetically 
measured for 30 min. Metabolically active cells reduce WST1 to a soluble red compound 
whose absorbance is directly proportional to the number of alive cells. Differences in 
absorbance between 30 and 0 min were determined, and means + sd calculated. 
D. Human fetal osteoblasts were seeded on the top of scaffolds S3 and grown for 6 weeks in 
the scaffolds. MTT was added to the culture medium bathing the scaffolds for 3 h, the 
scaffolds were washed and fixed in paraformaldehyde, and the upper and lower sides of the 
scaffolds were photographed. Metabolically active cells reduce MTT to a violet precipitate. 
Scaffolds without cells but exposed to MTT do not color in violet. In scaffold S3, cells can be 
found on both sides of the scaffolds. Experiments performed with scaffolds S1 in the same 
conditions for comparison demonstrate the presence of cells only on the up side of these 
scaffolds. 
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Figure 7: SEM micrographs of human fetal osteoblasts inside the scaffolds. 
Human fetal osteoblasts were grown for 6 weeks in scaffold S3. After fixation in 
paraformaldehyde, the scaffold was split in the middle and the fracture section was scanned 
by SEM and SEM pictures of the cells inside the scaffolds taken, showing that the cells 
adhered and spread onto the ceramic materials at all levels of the materials.  
a) cross-section of a S3 scaffold, unidirectionally seeded (seeding direction from top to 
bottom) with fetal osteoblasts and cultured in the scaffolds for 6 weeks; bar = 200 μm.   
b) close ups of the cells indicated by a number (1 to 9) in (a). For improved viewing, the cells 
in the scaffolds were outlined with white lines except in panels b6 and b7 where most of the 
area is covered by cells; bars = 5 μm. 
 
Figure 8. Enhancement of rapid adhesion of the human fetal osteoblasts by click-
functionalization of the scaffolds. 
A: Disks of scaffolds functionalized with 0, 5, or 10 μM of compound 5 were incubated with 
FtOs for 1 h, then the cells were stained and photographed.  
B: The quantification of the number of adhered cells was performed by analysis of 
stereomicroscopy pictures. Results are the mean ± sd of triplicates of three independent 
experiments. The number of cells adhering to the bio-ceramics disks was compared among 
unfunctionalized scaffolds (0 μM) and scaffolds functionalized with compound 5 (5 μM or 10 
μM) using a Student’s t-test : *** : p < 0.001. The correlation coefficient was caculated 
between the number of adhered cells on scaffolds functionalized with 5 μM and 10 μM of 
compound 5 : r = 1.00. 
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Figures 
 
 
 
Figure 1: Macroscopic and microscopic aspect of the scaffolds. 
Upper panel: a) macrophotographs of the three different scaffold materials (from left to right: 
scaffold S1, scaffold S2 and two pictures of scaffold S3);  
Lower panels: SEM micrographs of b) scaffold S1; c) scaffold S2; d) scaffold S3. 
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Figure 2: Size distribution of the pores and pore openings for the 3 different scaffolds.  
To define the diameters of the pores and pore-openings, SEM micrographs at low 
magnifications were analyzed (grey bars) using the software Linear Intercept, then the 
cumulative values were calculated (solid lines).  
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Figure 3: Determination of the proliferation of human U2Os osteosarcoma cells 1 to 3 days 
after seeding in the scaffolds.   
To evaluate for cell proliferation in the scaffolds, U2Os cells were seeded onto one of each of 
the three scaffolds (S1, S2, S3) and culture was performed for 24 h. AlamarBlue was added to 
the cells-scaffolds and fluorescence measured after 45 min. Then, fresh medium was added 
and culture continued and the process was repeated after 48 h and 72 h of cell culture in the 
scaffolds, allowing the same cell-scaffold system to be sequentially analyzed on day 1, day 2 
and day 3. ♦ scaffold S1; □ scaffold S2; ▲ scaffold S3. 
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Figure 4: SEM micrographs of human osteosarcoma cells inside the scaffolds. 
A. Human SaOs (upper panels) and U2Os (lower panels) osteosarcoma cells were grown in 
scaffold S1 (S1), scaffold S2 (S2) or scaffold S3 (S3) for, respectively, 1 day or 4 days. After 
fixation in paraformaldehyde, the scaffolds were split and SEM pictures of the cells inside the 
scaffolds taken, showing that the cells adhered and spread onto the ceramic materials. White 
arrows indicate the cells. 
B. Human U2Os osteosarcoma cells were unidirectionally (red arrow) seeded on the top of 
scaffold and grown for 4 days in scaffold S3. Then the scaffold was fixed in 
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paraformaldehyde, split in the middle and the fracture section was scanned by SEM. Isolated 
cells (labeled 1-5) are shown at higher magnification in panels 1-5. For improved viewing, the 
cell shapes are surrounded by a white line.  
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Figure 5: Expression of collagen I, alkaline phosphatase activity and calcium deposits by the 
human bone-derived cells. 
A. Human cells (skin fibroblasts, fetal osteoblasts (FSOS), and osteosarcoma cells (SaOs, 
U2Os)) were grown to confluence in Petri dishes and extracted. Cell extracts were submitted 
to western blotting experiments using an anti-human collagen I antibody, and loading was 
controlled using an anti-human α-tubulin antibody. When the cells were grown in 
differentiating medium for 7 to 14 days, no induction of collagen I expression by U2Os and 
SaOs cells and no further enhancement of collagen I expression by FsOs cells by 
differentiation medium was observed (not shown). 
B. Alkaline phosphatase activity (U/mg protein) was determined in human fetal osteoblasts 
(FsOs), and osteosarcoma cells (SaOs, U2Os) grown either in standard or in differentiating 
culture medium (diff) for 10 days. Means of triplicate wells + sd were calculated. 
Experiments were repeated 3 times with similar information. No further enhancement of 
alkaline phosphatase activity by FsOs cells by differentiation medium was observed for 
longer culture in differentiation medium (not shown). 
C. Kossa staining of calcium deposits (black staining, arrows) in terminally differentiated, 
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non-proliferating human fetal osteoblasts. Cell cytoplasms are stained light pink and cell 
nuclei dark pink. 
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Figure 6: Human fetal osteoblasts grown in scaffold S3 are retained, proliferate and are 
metabolically active in the scaffolds for at least 6 weeks.  
A. Human fetal osteoblasts were prelabeled with [3H]-thymidine, then grown in the scaffolds 
for 2 or 6 days. Radioactivity was quantified in extracts of the cells in the scaffolds (dark 
grey), associated to the cells at the bottom of the wells (light grey) and in the soluble culture 
media (black). The experiments were repeated twice, with comparable information.  
B. Human fetal osteoblasts were grown in scaffolds S3 for 6 days. After fixation in 
paraformaldehyde, the scaffolds were split and SEM pictures of the cells inside the scaffolds 
taken, showing that the cells adhered and moved into the ceramic materials, spanning across 
the pores in the selected SEM picture.  
C. Human fetal osteoblasts were seeded on scaffold S3 and grown in culture medium. After 7, 
14, 21 and 38 days of osteoblast culture in the scaffolds, WST-1 was added to the culture 
medium bathing the scaffolds (2-3 scaffolds per time-point) and absorbance kinetically 
measured for 30 min. Metabolically active cells reduce WST1 to a soluble red compound 
whose absorbance is directly proportional to the number of alive cells. Differences in 
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absorbance between 30 and 0 min were determined, and means + sd calculated. 
D. Human fetal osteoblasts were seeded on the top of scaffolds S3 and grown for 6 weeks in 
the scaffolds. MTT was added to the culture medium bathing the scaffolds for 3 h, the 
scaffolds were washed and fixed in paraformaldehyde, and the upper and lower sides of the 
scaffolds were photographed. Metabolically active cells reduce MTT to a violet precipitate. 
Scaffolds without cells but exposed to MTT do not color in violet. In scaffold S3, cells can be 
found on both sides of the scaffolds. Experiments performed with scaffolds S1 in the same 
conditions for comparison demonstrate the presence of cells only on the up side of these 
scaffolds. 
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Figure 7: SEM micrographs of human fetal osteoblasts inside the scaffolds. 
Human fetal osteoblasts were grown for 6 weeks in scaffold S3. After fixation in 
paraformaldehyde, the scaffold was split in the middle and the fracture section was scanned 
by SEM and SEM pictures of the cells inside the scaffolds taken, showing that the cells 
adhered and spread onto the ceramic materials at all levels of the materials.  
a) cross-section of a S3 scaffold, unidirectionally seeded (seeding direction from top to 
bottom) with fetal osteoblasts and cultured in the scaffolds for 6 weeks; bar = 200 μm.   
b) close ups of the cells indicated by a number (1 to 9) in (a). For improved viewing, the cells 
in the scaffolds were outlined with white lines except in panels b6 and b7 where most of the 
area is covered by cells; bars = 5 μm. 
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Figure 8. Enhancement of rapid adhesion of human fetal osteoblasts by click-
functionalization of the scaffolds. 
A: Disks of scaffolds functionalized with 0, 5, or 10 μM of compound 5 were incubated with 
FtOs for 1 h, then the cells were stained and photographed.  
B: The quantification of the number of adhered cells was performed by analysis of 
stereomicroscopy pictures. Results are the mean ± sd of triplicates of three independent 
experiments. The number of cells adhering to the bio-ceramics disks was compared among 
unfunctionalized scaffolds (0 μM) and scaffolds functionalized with compound 5 (5 μM or 10 
μM) using a Student’s t-test : *** : p < 0.001. The correlation coefficient was caculated 
between the number of adhered cells on scaffolds functionalized with 5 μM and 10 μM of 
compound 5 : r = 1.00. 
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TOC 
Foam scaffolds of calcium alumina permissive for trans-scaffold migration and proliferation 
of primary human fetal osteoblasts were developed and characterized as permanent implants 
for bone repair. 
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